Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

Oct 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Lilly's shares fall 8% as drug sales miss expectations CEO David Ricks cited physical and financial constraints at wholesalers for the shortfall Lilly slashes annual profit forecast due to ...